CeGaT

CeGaT is an established, privately-held German leader in genetic diagnostics and high-throughput sequencing services. The company serves a dual market of clinical diagnostics for rare diseases and oncology, alongside a robust B2B segment supporting pharmaceutical R&D and clinical trials. With a strong foundation in accredited laboratory operations and a continuous pipeline of service innovations like HiFi Whole Genome Sequencing and spatial transcriptomics, CeGaT is positioned at the intersection of precision medicine and advanced genomic research. Its business model is primarily service-based, generating revenue from diagnostic testing and contract research services.

High-throughput next-generation sequencing (NGS) platform specializing in long-read HiFi Whole Genome Sequencing, spatial transcriptome sequencing, multiplex immunofluorescence for tumor microenvironment analysis, and advanced bioinformatics interpretation.

CeGaT competes in a crowded global market for genetic diagnostics and sequencing services. Competitors range from large, international players like Illumina Clinical Services, Eurofins Genomics, and Quest Diagnostics, to specialized diagnostic firms like Centogene and many academic hospital labs. Its differentiation lies in its high-quality 'Made in Germany' accreditations, dual focus on clinical and pharma markets, and specialized offerings in long-read WGS and spatial biology.